Condition

Extensive-Stage Small Cell Lung Cancer

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 16 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials16
Recruiting4
Common interventions25
Lead sponsors shown15
Advertisement

Clinical trials

16 shown
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory DiseaseNCT07509034 · 2026-10-12
RECRUITING
A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)NCT07652736 · 2026-06-05
RECRUITING
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).NCT06646276 · 2025-02-25
RECRUITING
Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLCNCT06497530 · 2024-12-01
RECRUITING
A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung CancerNCT07796100 · 2026-12-31
NOT_YET_RECRUITING
Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine CancerNCT07328490 · 2026-04-25
WITHDRAWN
Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLCNCT07388875 · 2026-02-24
NOT_YET_RECRUITING
A Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive-stage Small Cell Lung CancerNCT06614621 · 2025-02-01
NOT_YET_RECRUITING
Efficacy and Safety of Serplulimab With Chemotherapy and Aspirin in Untreated Extensive-Stage Small Cell Lung CancerNCT06554535 · 2024-10-01
NOT_YET_RECRUITING
MDT-Based Nursing for Small Cell Lung Cancer During Chemo-ImmunotherapyNCT07489339 · 2024-07-01
COMPLETED
Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung CancerNCT05509699 · 2022-09-27
COMPLETED
A Study of SYHA1807 in Subjects With Extensive-Stage Small Cell Lung CancerNCT04404543 · 2020-06-01
UNKNOWN
Efficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide ChemotherapyNCT04056949 · 2019-08-05
UNKNOWN
Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study)NCT01555710 · 2012-06-08
TERMINATED
A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung CancerNCT01076504 · 2009-12-01
COMPLETED
Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLCNCT00616109 · 2007-09-01
COMPLETED

Common interventions

Leading sponsors

Trial status mix

COMPLETED4
NOT_YET_RECRUITING4
RECRUITING4
UNKNOWN2
TERMINATED1
WITHDRAWN1

Phase mix

PHASE29
PHASE13
PHASE33
NA1
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.